超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Oxford Biomedical Research  
Oxford Biomedical Research（OBR）公司由Denis M. Callewaert博士于1984年建立。OBR公司開發，生產和銷售檢測試劑盒，重組蛋白和應用于生物醫學和制藥研究的抗體，現已具有400多種產品。我們產品的重點是對引發多種疾病的兩大風險因素氧化應激和慢性炎癥的生物標志物的識別與檢測。我們采用專有技術，開發組織和疾病的特異性生物標志物。

檢測試劑盒
OBR公司擁有超過25年的開發和生產ELISA檢測試劑盒經驗，專注于類花生酸代謝、氧化壓力、蛋白質組、信號轉導、心血管生物學和的ELISA檢測。
Oxford Biomedical Research (OBR) develops, manufactures and markets assay kits, recombinant proteins and antibodies for biomedical research and drug discovery. Our primary focus is on the identification and assay of biomarkers for oxidative stress and chronic inflammation, two major risk factors for multiple diseases. We employ proprietary technology to develop tissue and disease specific biomarkers.

Mission Statement
Recognizing that the reduction in disease and improvement of human health will require the development of better ways to identify and quantify underlying risk factors for disease, Oxford Biomedical Research (OBR) seeks to provide biomedical researchers with the best tools available for the analysis of Oxidative Stress and Chronic Inflammation – two of the most important risk factors that play key roles in the development of a wide range of human illness, including cancer, cardiovascular disease, diabetes and neurodegeneration.

Vision Statement
In contrast to current medical and insurance practices focused on the treatment of diseases, we seek to provide biomedical researchers and diagnosticians with reliable, non-invasive methods for the assessment of oxidative stress and chronic inflammation and the efficacy of diet, drugs, nutraceuticals, and lifestyle for the prevention of major debilitating diseases.

Corporate Profile
Oxford Biomedical Research (OBR) develops, manufactures and markets assay kits, recombinant proteins and antibodies for biomedical research and drug discovery. The company’s primary focus is on the identification and assay of biomarkers for oxidative stress and chronic inflammation, two major risk factors for multiple diseases. OBR is employing proprietary technology to develop tissue and disease specific biomarkers. ProteoMine? is a cost effective tool for removing high abundance proteins for biomarker discovery. ToxProfiler? technology captures and detects oxidized proteins in blood correlated with organ-specific toxicity and disease. New platform technologies such as Toxicoproteomics and Metabolomics are being applied, adapted and modified into new and practical ways for the diagnosis of early onset disease and for the prevention of diseases.

History
Oxford Biomedical Research (OBR) was founded in 1984 by Denis M. Callewaert Ph.D., Professor of Chemistry and the former Director of the Center for Biomedical Research at Oakland University. It is one of 4 biotechnology companies founded by Professor Callewaert.
Located in Rochester Hills, MI, the Company markets over 800 products for the biomedical research community.
Oxford Biomedical Research also performs research and development under the auspices of grants and contracts from the National Institute of Health.
OBR has developed a large number of collaborations with internationally recognized scientists. The Company has licensed several key technologies and is further developing clinical diagnostic tests in collaboration with faculty from major academic and government research institutions.

Partnerships
The company actively seeks partnerships in related fields of study to combine strengths and abilities. Please contact us to discuss opportunities.

SBH Sciences is a Biotechnology Service Provider company offering comprehensive preclinical process development services to the biopharmaceutical, diagnostics and biotechnology industries including cell culture (mammalian and insect cell), protein purification, cell-based assays and ELISA Development kit. In addition, SBH Sciences is producing 30 monoclonal antibodies and 25 highly purified recombinant cytokines including Activin A, BMP-7, HGF, Interleukin-12 and TGF-b.